Aurobindo Pharma's Eugia Pharma approved to manufacture Dasatinib Tablets, a bioequivalent to Bristol-Myers Squibb's Sprycel, ...

The up move in the stock came after the company arm Eugia Pharma Specialities, received final approval from USFDA to ...

Aurobindo Pharma's shares rose nearly 3% after its subsidiary, Eugia Pharma, received USFDA approval to market Dasatinib ...

Aurobindo Pharma rose 1.81% to Rs 1,209.60 after its wholly owned subsidiary, Eugia Pharma Specialities, received final approval from the U.S. Food and Drug Administration (USFDA) to manufacture and ...

Eugia Pharma, a subsidiary of Aurobindo Pharma, has secured final USFDA approval for manufacturing and marketing Dasatinib ...

Benchmark NSE Nifty50 index ended up 161.71 points at 24328.95, while the BSE Sensex stood up 520.9 points at 80116.49. Among ...

Patent pool is a consortium of two or more patent-holders to promote a particular technology and share the market ...

The Nifty reclaimed the 24,300 mark, ending the day at 24,329 after a gain of 162 points, while the Sensex surged 521 points ...

Indian equities extended gains for the seventh straight session on Wednesday, with the BSE Sensex jumping 520.90 points (0.65 ...

After a consistent five-day rally, the market may consolidate, though the overall trend remains positive. Below are some ...

thanks to its lower share of revenue from the US market compared to rivals with higher US revenue dependencies – almost 46% for Zydus Lifesciences and 47% for Aurobindo Pharma. Execution and ...

India supplies over 45% of the generics and 15% of biosimilars used in the U.S., with major companies like Dr. Reddy’s, Aurobindo Pharma, Zydus Lifesciences, Sun Pharma, and Gland Pharma earning ...